No promotion of MDR-TB medicines to mitigate against overselling and prolong their effectiveness
Johnson & Johnson, Otsuka
Johnson & Johnson and Otsuka do not use sales agents to promote their multidrug-resistant tuberculosis medicines in order to prevent the risk of resistance.
One of the main drivers for AMR is the overuse and misuse of antimicrobial products, causing antimicrobials to become ineffective more rapidly. Sales practices can promote overuse and misuse, especially when company business models rely on making high volumes of sales. To avoid this, pharmaceutical companies should take steps to ensure their products are used appropriately and only when needed. In choosing not to promote their products, companies can lower the risk of inappropriate use and help limit the spread of resistance.
How do two companies represent best practice?
Johnson & Johnson and Otsuka both demonstrate best practice by choosing not to use sales agents to promote their medicines for multidrug-resistant tuberculosis (MDR-TB): Johnson & Johnson for bedaquiline (Sirturo®) and Otsuka for delamanid (Deltyba™). This practice helps to prevent any inappropriate use. Given the comparatively wide spread of extensively drug-resistant and multi-drug resistant tuberculosis strains, the stewardship of tuberculosis medicines is prioritised by global health and national public health bodies.